Preferred Providers 

Revolutionizing the Face of Addiction Treatment

 Thrive’s 7 Principles of Recovery Treatment:

  • Institutional reinforcement of learned helplessness is rarely appropriate.
  • The power of positive thinking and the placebo effect are powerful forces.
  • Treat the body and the mind will follow.
  • Indeterminate open-ended therapy lengths are never helpful for the patient’s psyche and trust.
  • Faith, hope, encouragement, and support are vital to the success of an individual.
  • Patients in recovery require a lifetime of diligence and continual awareness to ensure success.
  • Sometimes, despite our best efforts, we don’t achieve the results we are hoping for.

 Advancing Better Practices and a Realistic Approaches To:

  • Opiate addiction and management
  • Alcohol addiction
  • Erectile dysfunction 
  • Will never require a prior authorization

 *-Only 3 drugs are approved for "Medication Assisted Treatment" according to SAMHSA (Substance Abuse Mental Health Services Guidelines): Buprenorphine, Naltrexone, and Methadone. We do not carry methadone (a schedule II medication). Clinical studies indicate sublingual and injectable buprenorphine may effectively manage opioid addiction. As a prescriber you understand you use your full authority and judgment to prescribe buprenorphine. The benefit of exercising such judgment may increase the patient’s compliance and success due to it’s cost-effectiveness. Well-insured patients may be better suited with the commercially available products. Our compounded troche is less subject to diversion through selling, injecting, or snorting. For the treatment of alcoholism, We are compounding "Altrexone" Capsules, our trademarked name of the first ever combination of low-dose disulfiram with naltrexone when abstinence truly is the only option (vs the Sinclair method).  See "Thrive Sheet for Providers"- PDFs on the resources PDF link page.

     If treating chronic pain, buprenorphine is increasingly becoming first line therapy as it has a ceiling effect on respiratory depression and has a MME potency of approx 15mg morphine per 1mg buprenorphine (many discrepancies exist with these "conversion tables" so use your clinical judgment). For non-malignant chronic pain, or, to "get Grandma off of Oxycodone" (plus the rest of the eligible population), consider this schedule III that was developed in 1968 to compete against morphine. 

Together let’s improve lives and EMPOWER our patients to THRIVE.

Join Our Preferred Provider Program!

If you are interested in joining our provider network, please download and submit the appropriate application packet below. 

Preferred Provider Form

Loading Form..